Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

Clinical trial NCT05383716 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05383716
Sponsor: Peking Union Medical College Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Neoadjuvant Therapy Immune Checkpoint Inhibitor

Start date: 2022-07-01
Primary completion: 2023-12-08
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.